Bortezomib
An FDA-approved first-in-class reversible proteasome inhibitor — a dipeptide boronic acid — that defined modern multiple myeloma therapy and the peptide-boronate drug class.
What is Bortezomib?
Bortezomib is a synthetic dipeptide boronic acid (a phenylalanine-leucine backbone capped with a boronic-acid warhead) that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. It was the first-in-class proteasome inhibitor and received accelerated FDA approval in 2003 for relapsed multiple myeloma, with expanded approvals following for mantle cell lymphoma and front-line multiple myeloma. Bortezomib is a foundational drug of modern plasma-cell-neoplasm therapy and defined the peptide-boronate drug class, which went on to include the second-generation agents carfilzomib (Kyprolis) and ixazomib (Ninlaro).
What Bortezomib Is Investigated For
Bortezomib is an FDA-approved proteasome inhibitor used across plasma-cell neoplasms — relapsed multiple myeloma (2003 accelerated approval via the SUMMIT Phase 2 trial, full approval via the APEX Phase 3 trial), front-line multiple myeloma (2008 VISTA Phase 3 approval with melphalan and prednisone), and mantle cell lymphoma (2006 PINNACLE Phase 2, expanded to front-line MCL in 2014). It is the anchor of modern triplet and quadruplet induction regimens (VCd, VRd, VTd, Dara-VMP, Dara-VRd) and a standard choice for AL amyloidosis and for antibody-mediated rejection in the transplant world. The strongest evidence is in multiple myeloma, where bortezomib-containing regimens produce higher response rates, deeper responses, and longer survival than non-proteasome-inhibitor alternatives across repeated Phase 3 randomised trials and network meta-analyses. The honest caveats are real: peripheral neuropathy is the defining adverse effect and is the main reason for dose modification or early discontinuation, though the switch from twice-weekly intravenous to subcutaneous or weekly dosing (per the Moreau MMY-3021 trial) substantially reduces neuropathy without sacrificing efficacy; herpes zoster reactivation is common without acyclovir prophylaxis; thrombocytopenia is cyclical and usually manageable; cardiac and pulmonary toxicity is uncommon but reported. Resistance inevitably develops on long-term exposure, and the second-generation proteasome inhibitors (carfilzomib, ixazomib) and non-PI mechanisms (anti-CD38 antibodies, BCMA-directed therapy) have built out the myeloma toolkit around — not in replacement of — bortezomib. This is a hospital-prescribed oncology drug, not a wellness peptide.
History & Discovery
Bortezomib's origin story is one of the cleaner examples of rational drug design in modern oncology. In the early 1990s, Julian Adams and colleagues at Myogenics (later renamed ProScript), a small Cambridge, Massachusetts biotech, were exploring the ubiquitin-proteasome system as a therapeutic target. The biology was already compelling — the proteasome is the cell's major machinery for regulated protein degradation, and work in the Goldberg and Rechsteiner laboratories had established its central role in cell-cycle control, NF-κB signalling (via IκB degradation), and protein quality control. What was missing was a drug-like, selective inhibitor. The team synthesized a series of dipeptidyl boronic acids — peptide-mimetic compounds with a boronic-acid warhead designed to form a reversible tetrahedral adduct with the catalytic threonine of the proteasome β5 active site. The lead compound, originally designated MG-341 and then PS-341, was reported in the seminal 1999 Cancer Research paper by Adams et al. with broad preclinical anti-tumor activity. ProScript was acquired by Leukosite, which was in turn acquired by Millennium Pharmaceuticals in 1999. Millennium advanced PS-341 into Phase 1 trials at the NCI and clinical centers including Dana-Farber, where a striking response signal in multiple myeloma — a cancer with no new drug class approved in nearly a decade — pushed the program toward a focused Phase 2 trial in relapsed, refractory myeloma. That trial was the Richardson et al. SUMMIT study (NEJM, 2003), a 202-patient open-label Phase 2 that produced a 35% response rate in patients with advanced disease who had exhausted standard therapy. The FDA granted accelerated approval on May 13, 2003 — less than a decade from the first synthesis of the compound. The confirmatory APEX Phase 3 trial (Richardson et al., NEJM, 2005) in 669 relapsed myeloma patients compared bortezomib to high-dose dexamethasone, was halted early for efficacy, and converted the accelerated approval into full approval. Expanded indications followed: relapsed/refractory mantle cell lymphoma (2006, PINNACLE Phase 2), front-line multiple myeloma in combination with melphalan and prednisone (2008, San Miguel et al. VISTA Phase 3), and front-line mantle cell lymphoma in combination with rituximab/cyclophosphamide/doxorubicin/prednisone (2014). Takeda acquired Millennium in 2008 for $8.8 billion, largely on the strength of the bortezomib franchise. Velcade became one of the highest-grossing oncology products of its era and is now one of the most widely used hematologic-oncology drugs in the world. Crucially, bortezomib established the entire peptide-boronate drug class: the second-generation intravenous proteasome inhibitor carfilzomib (Kyprolis, Amgen) — an irreversible epoxyketone — was approved in 2012, and the first oral proteasome inhibitor ixazomib (Ninlaro, Takeda) — a peptide-boronate successor — was approved in 2015. The transition from twice-weekly IV dosing to subcutaneous administration was driven by the Moreau et al. MMY-3021 Phase 3 trial (Lancet Oncology, 2011), which showed non-inferior efficacy with roughly half the rate of peripheral neuropathy, and subcutaneous bortezomib became the standard of care for most indications by the mid-2010s. US composition-of-matter patents on the originator product began expiring in the late 2010s, and multiple bortezomib generic and biosimilar-equivalent formulations are now available across the US, EU, and major Asian markets.
How It Works
Cells constantly produce proteins, and a substantial fraction of them are misfolded or no longer needed. The proteasome is the cell's protein shredder — a barrel-shaped complex that grinds them back into amino acids. Bortezomib jams the shredder. Plasma cells (and the malignant myeloma cells derived from them) churn out vast amounts of immunoglobulin protein and depend heavily on the proteasome to clear the misfolded byproducts. When bortezomib blocks that clearance, misfolded protein accumulates to lethal levels and the cells die — selectively in cell types that already live near the edge of proteostatic failure.
Bortezomib is a reversible, slow-off-rate inhibitor of the 26S proteasome. The boronic-acid warhead forms a tetrahedral adduct with the N-terminal threonine (Thr1) hydroxyl of the proteasome's β5 chymotrypsin-like catalytic subunit, with secondary activity at the β1 caspase-like subunit and minimal activity at the β2 trypsin-like site. The crystal structure of bortezomib bound to the yeast 20S proteasome (Groll et al., 2006) confirmed this binding mode and explained the peptide-boronate class's specificity. The downstream consequences of proteasome inhibition are pleiotropic, but three pathways dominate the anti-myeloma effect. First, stabilisation of IκBα prevents NF-κB nuclear translocation, removing a pro-survival signalling input that myeloma cells and their bone-marrow microenvironment depend on. Second, accumulation of polyubiquitinated misfolded protein triggers a terminal unfolded protein response (UPR) that, in plasma-lineage cells already operating at high immunoglobulin-synthesis load, pushes ER stress past the point of adaptive rescue and into apoptosis. Third, stabilisation of pro-apoptotic regulators (p53, NOXA, Bik) and cell-cycle inhibitors (p21, p27) shifts the intracellular balance toward cell death. The convergence of these effects — along with overlapping sensitivity in mantle cell lymphoma, where NF-κB dependence and cyclin D1 dysregulation create similar vulnerabilities — defines the drug's clinical footprint.
Evidence Snapshot
Human Clinical Evidence
Extensive. Foundational Phase 2 (SUMMIT), Phase 3 (APEX, VISTA, PINNACLE, MMY-3021, IFM 2005-01, ENDEAVOR) trials plus decades of real-world use across multiple myeloma, mantle cell lymphoma, and AL amyloidosis.
Animal / Preclinical
Comprehensive. Adams and colleagues (1999) demonstrated broad preclinical anti-tumor activity and established the peptide-boronate proteasome-inhibitor class.
Mechanistic Rationale
Very strong. 26S proteasome β5 binding is crystallographically defined, and plasma-cell UPR/NF-κB dependence is mechanistically well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Bortezomib:
- 01Predictors of peripheral neuropathy — genetic and clinical factors that reliably identify patients at high risk for severe or disabling bortezomib-induced peripheral neuropathy remain incompletely characterized; several pharmacogenomic signals have been reported but none is clinically actionable.
- 02Optimal integration with immunotherapy — the relative sequencing of bortezomib-containing regimens with CAR-T (idecabtagene, ciltacabtagene), bispecific antibodies (teclistamab), and anti-CD38 monoclonals in modern multi-line myeloma pathways continues to evolve.
- 03Mechanisms of acquired resistance — proteasome-subunit mutations, compensatory autophagy upregulation, and altered UPR signalling all contribute to resistance, but a unifying framework for predicting and reversing resistance is not yet established.
- 04Role in maintenance and post-transplant continuation — the optimal duration and dose intensity of bortezomib-based maintenance vs. lenalidomide maintenance vs. combination maintenance in high-risk myeloma is an active research question.
- 05Cardiovascular and pulmonary toxicity signal — rare but real reports of reversible cardiomyopathy and acute infiltrative lung disease are not well-characterized; predictors and mechanism remain unclear.
- 06Role in non-hematologic indications — bortezomib has been investigated in solid tumors, systemic sclerosis, antibody-mediated renal transplant rejection, and other non-oncologic indications with mixed results; whether there is a durable non-hematologic niche is unresolved.
Forms & Administration
Intravenous bolus or subcutaneous injection at 1.3 mg/m² on days 1, 4, 8, 11 of each 21-day cycle (twice-weekly standard) or days 1, 8, 15, 22 of each 35-day cycle (weekly schedule). Subcutaneous dosing is now preferred over IV because of lower peripheral neuropathy incidence with non-inferior efficacy. Bortezomib is a hospital- and specialty-infusion-center-administered oncology drug; it is not self-administered or used outside of cancer care. All doses must be given by a qualified oncology provider under a defined treatment protocol.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
1.3 mg/m² body surface area per dose. The standard schedule is twice-weekly bortezomib on days 1, 4, 8, and 11 of a 21-day cycle, typically for 6–8 cycles in relapsed disease or 8–9 cycles in front-line VMP regimens, often followed by a less-intensive maintenance or continuation schedule. A weekly schedule (days 1, 8, 15, 22 of a 35-day cycle) is widely used in front-line VMP and VRd regimens and produces lower peripheral-neuropathy rates with comparable efficacy in the transplant-ineligible front-line setting.
Frequency
Subcutaneous injection (preferred route as of the MMY-3021 trial, 2011) or intravenous bolus (2–5 seconds), given in an oncology infusion center or hospital under direct supervision. Consecutive doses must be separated by at least 72 hours. Dose reductions to 1.0 mg/m² or 0.7 mg/m² — or schedule reduction from twice-weekly to weekly — are standard for emergent peripheral neuropathy or hematologic toxicity, per the APEX dose-modification guideline.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Twice-weekly schedule: 21-day cycles, typically 6–8 cycles. Weekly schedule: 35-day cycles. Induction regimens before autologous stem-cell transplant run 3–6 cycles. Maintenance bortezomib (every 2 weeks) has been used in high-risk myeloma and in the HOVON/GMMG programs. Total treatment duration is individualized based on response, tolerability, transplant eligibility, and the specific combination regimen (VCd, VRd, VTd, Dara-VMP, Dara-VRd, etc.).
Protocol Notes
Bortezomib is almost always given as part of a combination regimen rather than monotherapy in modern myeloma practice. Common frontline combinations include VRd (bortezomib + lenalidomide + dexamethasone) for transplant-eligible and transplant-ineligible newly diagnosed myeloma; VMP (bortezomib + melphalan + prednisone) for older transplant-ineligible patients (the VISTA regimen); and daratumumab-containing quadruplets (Dara-VRd, Dara-VMP). In mantle cell lymphoma, bortezomib replaces vincristine in modified CHOP regimens (VR-CAP). In AL amyloidosis, bortezomib + cyclophosphamide + dexamethasone (VCd) is a standard front-line option alongside daratumumab-based regimens. Peripheral-neuropathy monitoring is the single most important ongoing management task: clinicians assess neuropathy grade at every cycle and follow an established dose-modification algorithm (the APEX guideline). Any grade 2 neuropathy with pain or grade 3 neuropathy triggers dose reduction or holding the drug; grade 4 neuropathy requires permanent discontinuation. Switching from IV to subcutaneous dosing, and from twice-weekly to weekly scheduling, are the two interventions with the best evidence for neuropathy mitigation. Acyclovir prophylaxis (typically 400 mg orally once daily) is standard throughout bortezomib therapy and for a period after completion to prevent herpes zoster reactivation — without prophylaxis, zoster incidence approaches 10–15% on bortezomib, and is cut close to zero with low-dose acyclovir. Complete blood count monitoring is cycle-by-cycle; thrombocytopenia is cyclical (nadir typically day 11) and usually recovers between cycles without transfusion. Baseline and periodic assessment of hepatic function, renal function, and cardiac status are part of standard oncology supportive care. Subcutaneous reconstitution uses a higher concentration than IV (2.5 mg/mL vs 1 mg/mL) to keep injection volume manageable. Rotation of injection sites (thigh, abdomen) minimizes local reactions, which are more common with SC than IV dosing but are usually mild and self-limited.
Bortezomib is an FDA-approved oncology drug for multiple myeloma and mantle cell lymphoma. It must be prescribed and administered only by an oncologist or hematologist in an appropriate supervised infusion-center or hospital setting, as part of a defined treatment protocol. It is not a peptide for self-administration and has no role in wellness, performance, or anti-aging use. Dose-reduction and discontinuation thresholds for peripheral neuropathy and hematologic toxicity must be followed strictly.
Timeline of Effects
Onset
Proteasome inhibition is detectable in peripheral blood within 1 hour of administration, with peak inhibition (typically 60–80%) of the chymotrypsin-like activity within 1–2 hours and measurable recovery over 24–72 hours between doses. Clinical tumor response — decline in monoclonal protein in myeloma or radiographic response in lymphoma — typically emerges over the first 2–4 cycles of therapy (approximately 6–12 weeks).
Peak Effect
In multiple myeloma, maximal response is commonly observed by cycles 4–8 of therapy. The APEX and VISTA trials reported overall response rates of 38% and 71% respectively, with deepening of response (VGPR, near-CR, CR) typically accumulating through cycles 6–8. In mantle cell lymphoma, PINNACLE reported 33% overall response, typically reached within the first 2–3 cycles. Continuation or maintenance dosing beyond the induction phase preserves rather than substantially deepens response.
After Discontinuation
Proteasome activity recovers to baseline within hours to days of a missed dose. The anti-tumor effect of a completed course persists for weeks to months depending on disease biology; in myeloma, relapse after a bortezomib-containing induction typically emerges over 12–36 months depending on maintenance strategy and disease risk. Peripheral neuropathy often improves over months but may be incompletely reversible, particularly with cumulative exposure beyond approximately 45 mg/m². Herpes zoster risk declines after treatment completion but acyclovir prophylaxis is typically continued for weeks after the final dose.
Common Questions
Who Bortezomib Is NOT For
- •Known hypersensitivity to bortezomib, boron, or mannitol (formulation excipient).
- •Pregnancy — bortezomib is embryotoxic and fetotoxic in animal studies; pregnancy must be excluded before treatment and effective contraception is required during and for a defined interval after therapy in both female patients and female partners of male patients.
- •Breastfeeding — not recommended during bortezomib therapy.
- •Acute diffuse infiltrative pulmonary and pericardial disease — rare but reported; prior episodes are a relative contraindication to continued therapy.
- •Severe hepatic impairment — dose reduction is required; use is cautious and may be contraindicated in the most severe cases.
- •Pre-existing severe peripheral neuropathy (grade 2 with pain or grade 3+) — relative contraindication; if treatment is still indicated, weekly subcutaneous dosing at reduced dose level is preferred.
- •Concurrent intrathecal administration — bortezomib is for IV or SC use only; intrathecal administration has resulted in fatalities and is contraindicated.
Drug & Supplement Interactions
Bortezomib undergoes oxidative metabolism predominantly via CYP3A4 and CYP2C19, with minor contributions from CYP1A2 and CYP2D6. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) increase bortezomib exposure by approximately 35%, with a corresponding increase in proteasome inhibition and potentially in toxicity; clinical monitoring is appropriate but co-administration is not absolutely contraindicated. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) reduce bortezomib exposure by approximately 45%, potentially compromising efficacy; concomitant use with rifampin in particular is not recommended. Pharmacodynamic interactions are more clinically important than PK interactions. Other neurotoxic agents (vincristine, platinum compounds, taxanes, thalidomide, lenalidomide) substantially increase the risk and severity of peripheral neuropathy when combined with bortezomib; the HOVON-65/GMMG-HD4 data and subsequent studies led to the replacement of vincristine with bortezomib in many lymphoma regimens specifically to reduce the cumulative neuropathy burden. Thalidomide + bortezomib (VTd induction) carries a higher neuropathy rate than lenalidomide + bortezomib (VRd); this is a driver of regimen selection. Oral hypoglycemic agents — bortezomib has been associated with both hyperglycemia and hypoglycemia; glucose-control regimens may require adjustment during therapy. Herpes zoster prophylaxis with low-dose acyclovir (typically 400 mg daily) is standard during bortezomib therapy to prevent reactivation; valacyclovir is an alternative. Live vaccines (varicella, zoster-live, yellow fever, MMR) should not be administered during or shortly after bortezomib therapy due to immunosuppression; inactivated vaccines are safe but immune response may be attenuated. As with any oncology specialty drug, all prescription, over-the-counter, and supplement use should be disclosed to the oncology team.
Safety Profile
Common Side Effects
Cautions
- • Pre-existing peripheral neuropathy — higher risk of severe or disabling neuropathy
- • Hepatic impairment — dose reduction required in moderate-to-severe impairment
- • Cardiac disease — rare but reported reversible cardiomyopathy and heart failure
- • Pulmonary disease — rare acute diffuse infiltrative lung disease reported
- • Pregnancy category-D equivalent — contraindicated; effective contraception required
- • Must be used only under oncologist / hematologist supervision in an infusion-center setting
What We Don't Know
Resistance mechanisms are incompletely characterized; predictors of which patients will develop severe neuropathy versus tolerate long-term therapy are not well defined.
Legal Status
United States
Velcade (bortezomib, Millennium/Takeda) received FDA accelerated approval in May 2003 for relapsed/refractory multiple myeloma, full approval in 2005, mantle cell lymphoma approval in 2006, front-line multiple myeloma approval in June 2008 (in combination with melphalan and prednisone), subcutaneous administration approval in January 2012, and front-line mantle cell lymphoma approval in October 2014 (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone). Originator patent expiry in the late 2010s opened the way for multiple generic bortezomib products. It is a prescription-only oncology specialty drug, not a controlled substance, and is dispensed and administered exclusively through oncology infusion centers and hospital pharmacies.
International
Approved by the EMA (Velcade, April 2004), UK MHRA, Health Canada, Australian TGA, PMDA (Japan), and most major regulatory authorities. Multiple generic bortezomib products are available across the EU, UK, and Asian markets. Included on the WHO Model List of Essential Medicines for the treatment of multiple myeloma.
Sports & Competition
Bortezomib is not a performance-enhancing drug and has no relevance to sport pharmacology. It is not named on the WADA Prohibited List. Therapeutic use in an oncology context would be managed through standard athlete medical-care channels.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Bortezomib is a pure peptide like BPC-157 or semaglutide.
Reality
It is a peptide-mimetic boronate — a synthetic dipeptide (Phe-Leu) capped with a boronic-acid warhead rather than a carboxylic acid. By strict structural definition it is a peptide-boronate small molecule, not a pure peptide. It is nonetheless the canonical member of the peptide-boronate drug class and is routinely included in peptide compendia, which is why it appears here. The distinction matters for regulatory framing (it is a small-molecule oncology drug, not a biologic) but does not change its mechanism or clinical footprint.
Myth
Bortezomib has been superseded by carfilzomib and ixazomib.
Reality
The second-generation proteasome inhibitors have expanded the class — carfilzomib offers irreversible binding and a different neuropathy profile, and ixazomib offers oral dosing — but bortezomib remains the most widely used proteasome inhibitor worldwide and is foundational to standard-of-care regimens including VRd, VMP, Dara-VMP, and Dara-VRd. The ENDEAVOR Phase 3 trial (carfilzomib vs bortezomib in relapsed myeloma) showed improved PFS and OS with carfilzomib at the doses studied, but also higher cardiac toxicity and cost; bortezomib, particularly with subcutaneous weekly dosing, remains the global workhorse.
Myth
Peripheral neuropathy on bortezomib is unavoidable and permanent.
Reality
Neuropathy is the defining adverse effect, but two large interventions substantially reduce it: subcutaneous administration (per the Moreau MMY-3021 trial, roughly half the rate of IV dosing) and weekly rather than twice-weekly scheduling. With modern SC weekly dosing and a standardized dose-modification algorithm, severe neuropathy is much less common than with the original twice-weekly IV schedule. Most neuropathy is partially or fully reversible after dose reduction or discontinuation, though cumulative exposure beyond roughly 45 mg/m² increases the chance of incomplete recovery.
Myth
Bortezomib is an immunosuppressant, so it works against cancer by suppressing the immune system.
Reality
This is the opposite of the mechanism. Bortezomib's anti-tumor effect derives from direct proteasome inhibition in malignant cells — plasma cells depend heavily on proteasomal clearance of misfolded immunoglobulin, and that dependence is the selective vulnerability. It does produce some immune-cell effects (including suppression of T-cell activation in the transplant-rejection setting), but these are secondary. The selective lethality to plasma-cell neoplasms is about proteostatic collapse in a protein-secreting cell type, not about general immunosuppression.
Myth
Because bortezomib inhibits the proteasome, it should be broadly useful across cancers.
Reality
Early clinical development tested bortezomib in many solid tumors (breast, lung, prostate, pancreatic, renal, urothelial) and produced largely disappointing results. The drug's clinical niche is hematologic — multiple myeloma, mantle cell lymphoma, and AL amyloidosis — where plasma-cell-lineage or B-cell NF-κB-dependent biology creates the selective vulnerability. Solid tumors, which do not share that degree of proteostatic and NF-κB dependence, generally do not respond. This is a classic example of how mechanism-agnostic 'broad applicability' can mislead; the right biology in the right disease matters.
Published Research
26 studiesTreatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis
The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Molecular mechanisms of acquired proteasome inhibitor resistance
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
The San Miguel et al. VISTA trial (NEJM, 2008) — the Phase 3 front-line study comparing melphalan-prednisone with or without bortezomib in 682 transplant-ineligible newly diagnosed myeloma patients. VMP extended time to progression from 16.6 to 24.0 months and produced a death-risk reduction vs. MP alone. The trial was the basis for FDA front-line approval in June 2008 and established bortezomib as foundational to front-line myeloma therapy.
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
The Groll et al. (Structure, 2006) crystallographic study at 2.8 Å resolution that defined bortezomib's binding mode at the proteasomal β5 chymotrypsin-like active site through a tetrahedral adduct with the N-terminal threonine. Seminal structural-biology paper that enabled rational design of the second-generation peptide-boronate and epoxyketone proteasome inhibitors.
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
The Richardson et al. APEX Phase 3 trial (NEJM, 2005) in 669 patients that converted bortezomib's accelerated approval into full approval: bortezomib versus high-dose dexamethasone produced higher response rates (38% vs 18%), longer time to progression, and improved overall survival, leading to early trial termination for efficacy. Definitive confirmatory evidence in relapsed myeloma.
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
A phase 2 study of bortezomib in relapsed, refractory myeloma
The Richardson et al. SUMMIT trial (NEJM, 2003) — the pivotal Phase 2 study in 202 patients with relapsed, refractory multiple myeloma that produced a 35% response rate with single-agent bortezomib. SUMMIT was the basis for FDA accelerated approval in May 2003 and established proteasome inhibition as a clinically valid strategy in plasma-cell malignancy. Landmark trial for the entire class.
Proteasome inhibitors: a novel class of potent and effective antitumor agents
The foundational Adams et al. (Cancer Research, 1999) paper from ProScript that defined the peptide-boronate proteasome-inhibitor class and established PS-341 (later bortezomib) as the lead compound. Reported broad preclinical anti-tumor activity in the NCI cell-line screen and in vivo efficacy in the PC-3 xenograft, and provided the structure-activity rationale for targeting the 26S proteasome with a dipeptidyl boronic acid. Seminal to the entire proteasome-inhibitor drug class.
Quick Facts
- Class
- Proteasome Inhibitor / Peptide Boronate
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 26PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.